15.64
price down icon0.57%   -0.09
pre-market  プレマーケット:  15.95   0.31   +1.98%
loading
前日終値:
$15.73
開ける:
$15.1
24時間の取引高:
3.06M
Relative Volume:
1.38
時価総額:
$1.85B
収益:
$59.61M
当期純損益:
$-262.14M
株価収益率:
-3.9898
EPS:
-3.92
ネットキャッシュフロー:
$-247.49M
1週間 パフォーマンス:
-9.54%
1か月 パフォーマンス:
+14.24%
6か月 パフォーマンス:
+68.17%
1年 パフォーマンス:
+57.82%
1日の値動き範囲:
Value
$14.76
$16.11
1週間の範囲:
Value
$14.76
$17.75
52週間の値動き範囲:
Value
$6.99
$17.75

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name
名前
Arcutis Biotherapeutics Inc
Name
セクター
Healthcare (1164)
Name
電話
805-418-5006
Name
住所
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Name
職員
342
Name
Twitter
@ArcutisBio
Name
次回の収益日
2024-12-06
Name
最新のSEC提出書
Name
ARQT's Discussions on Twitter

ARQT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ARQT
Arcutis Biotherapeutics Inc
15.64 1.85B 59.61M -262.14M -247.49M -3.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-30 開始されました H.C. Wainwright Buy
2024-08-28 開始されました Jefferies Buy
2024-01-03 アップグレード Mizuho Neutral → Buy
2023-10-26 ダウングレード Mizuho Buy → Neutral
2023-10-13 ダウングレード Goldman Buy → Neutral
2022-09-07 開始されました Needham Buy
2022-03-17 開始されました Goldman Buy
2021-06-30 開始されました Mizuho Buy
2021-05-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-11-09 アップグレード Goldman Neutral → Buy
2020-10-08 開始されました Truist Buy
2020-02-25 開始されました Cantor Fitzgerald Overweight
2020-02-25 開始されました Cowen Outperform
2020-02-25 開始されました Goldman Neutral
2020-02-25 開始されました Guggenheim Buy
すべてを表示

Arcutis Biotherapeutics Inc (ARQT) 最新ニュース

pulisher
Mar 31, 2025

Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com

Mar 31, 2025
pulisher
Mar 31, 2025

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - MSN

Mar 31, 2025
pulisher
Mar 30, 2025

Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - MSN

Mar 30, 2025
pulisher
Mar 28, 2025

Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Leading Immuno-Dermatology Player Arcutis Set for Major Investor Presentation at Needham Healthcare - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference - TradingView

Mar 27, 2025
pulisher
Mar 26, 2025

Arcutis Biotherapeutics CEO sells $64,413 in stock - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Arcutis Biotherapeutics CEO sells $64,413 in stock By Investing.com - Investing.com UK

Mar 26, 2025
pulisher
Mar 26, 2025

Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st

Mar 26, 2025
pulisher
Mar 25, 2025

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga

Mar 25, 2025
pulisher
Mar 24, 2025

Arcutis throws to Odell Beckham Jr., the latest face of Zoryve foam - Medical Marketing and Media

Mar 24, 2025
pulisher
Mar 20, 2025

Arcutis Biotherapeutics shares jump - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 - Investing.com India

Mar 20, 2025
pulisher
Mar 17, 2025

What's Going On With Arcutis Biotherapeutics Stock Monday? - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age - Quantisnow

Mar 17, 2025
pulisher
Mar 17, 2025

Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment - Marketscreener.com

Mar 17, 2025
pulisher
Mar 12, 2025

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha

Mar 12, 2025
pulisher
Mar 12, 2025

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada

Mar 11, 2025
pulisher
Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 10, 2025

Hand Eczema Clinical and Non-Clinical Studies, Key Companies, - openPR

Mar 10, 2025
pulisher
Mar 10, 2025

Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.00 - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - Simply Wall St

Mar 09, 2025
pulisher
Mar 07, 2025

Arcutis Biotherapeutics announces new data from two posters at 2025 AAD - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - The Manila Times

Mar 07, 2025
pulisher
Mar 07, 2025

Arcutis Biotherapeutics Inc (ARQT) Unveils Promising Data on ZORYVE® Cream and Foam at AAD 2025 - GuruFocus.com

Mar 07, 2025
pulisher
Mar 07, 2025

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic ... - The Bakersfield Californian

Mar 07, 2025
pulisher
Mar 07, 2025

Breakthrough Phase 3 Results: New Treatment Shows 97% Success Rate in Major Skin Conditions - StockTitan

Mar 07, 2025
pulisher
Mar 06, 2025

Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 06, 2025
pulisher
Mar 05, 2025

Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherape - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Seborrhoeic Dermatitis Clinical and Non-Clinical Studies, Key - openPR

Mar 05, 2025
pulisher
Mar 05, 2025

Arcutis Biotherapeutics CEO Todd Watanabe sells $327,019 in stock - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Arcutis Biotherapeutics (ARQT) – Research Analysts’ Recent Ratings Updates - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Arcutis Biotherapeutics Inc Stock: Executives Sell Shares Following Strong Results - sharewise

Mar 04, 2025
pulisher
Mar 04, 2025

Arcutis Biotherapeutics director sells $130,048 in stock By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Arcutis Biotherapeutics executive sells $49,407 in stock By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Arcutis Biotherapeutics executive sells $49,407 in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Arcutis Biotherapeutics’ general counsel Matsuda sells $42,520 in stock - Investing.com

Mar 04, 2025

Arcutis Biotherapeutics Inc (ARQT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):